Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences:
EnGene snags $60M: The Boston and Montreal gene therapy biotech raised the private placement from new and current investors a month after giving an early look at bladder cancer data. It’s the second big private placement for the biotech since it went public via a SPAC last fall. — Kyle LaHucik
AbbVie partners again with Gedeon Richter: The companies have worked together for nearly two decades, developing CNS medicines like the antipsychotic Vraylar, and now plan to collaborate on more neuropsychiatric drugs. The Budapest-based pharma company gets $25 million upfront in the new pact. — Kyle LaHucik
Tim Springer buys more shares of Tectonic Therapeutic: A repeat biotech builder and co-founder of Tectonic, Springer bought $10 million worth of shares from Atlas Ventures this week, according to an SEC filing. He owns about 31% of the company, which went public via a reverse merger this summer. — Kyle LaHucik
Molecular Partners prices $20M offering: The Swiss biotech said the raise from HBM Healthcare Investments and other investors will close next week, and the process will support its radiopharma pipeline. — Kyle LaHucik
Arcus Biosciences touts data from HIF-2a inhibitor in kidney cancer: The company shared Phase 1/1b data for casdatifan showing 81% of patients experienced disease control with either a partial response or stable disease. Other data demonstrated that 34% of patients experienced an objective response. It’s planning to start a Phase 3 trial of casdatifan in the first half of next year. The study is also enrolling another arm of patients to try out a combination of Arcus’ drug and Exelixis’ Cabometyx. — Katherine Lewin